QTREX Quantum (NASDAQ:QTEX) Stock Falls 9.8% – Here’s What Happened

Shares of QTREX Quantum Ltd. (NASDAQ:QTEX) dropped 9.8% during trading on Wednesday. The company traded as low as $1.01 and last traded at $1.01. Approximately 3,134,224 shares changed hands during mid-day trading, a decline of 62% from the average daily volume of 8,220,546 shares. The stock had previously closed at $1.12.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Weiss Ratings cut QTREX Quantum from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, October 9th. Wall Street Zen downgraded shares of QTREX Quantum from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat, QTREX Quantum presently has an average rating of “Sell”.

QTREX Quantum Price Performance

The firm has a 50-day simple moving average of $1.11. The company has a quick ratio of 1.62, a current ratio of 2.00 and a debt-to-equity ratio of 0.12.

QTREX Quantum (NASDAQ:QTEX) last announced its quarterly earnings results on Thursday, September 24th. The company reported ($0.07) earnings per share (EPS) for the quarter. The business had revenue of $0.78 million for the quarter.

Insider Activity

In related news, CEO Dagi Ben-Noon acquired 18,181 shares of the stock in a transaction dated Friday, October 9th. The shares were purchased at an average price of $1.67 per share, for a total transaction of $30,362.27. Following the transaction, the chief executive officer owned 3,664,314 shares in the company, valued at $6,119,404.38. This represents a 0.50% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. In the last 90 days, insiders acquired 207,834 shares of company stock worth $181,275. Insiders own 29.40% of the company’s stock.

About QTREX Quantum

Inspira Technologies OXY B.H.N. Ltd. is a medical technology company focused on developing advanced respiratory-support and blood-monitoring solutions for critical-care settings. The company’s technologies are intended to help address complications associated with respiratory failure and improve the management of patients requiring oxygenation support.

Its product portfolio includes the INSPIRA ART system, an extracorporeal respiratory-support platform designed to provide oxygenation while potentially reducing the need for conventional mechanical ventilation or more complex extracorporeal membrane oxygenation procedures.